Key mediators of the efficacy of mesenchymal stem cells on in vivo disease models
1Bioscience & Engineering Laboratory, Fujifilm Corporation, Kanagawa, Japan.
Abstract:
Mesenchymal stem cells (MSCs) are considered to be effective treatments for various diseases, and a wide variety of clinical studies have been performed worldwide. However, substantial obstacles remain before they can be approved and disseminated as treatments. A major bottleneck is the elucidation of their mechanisms of action, and the molecules that are essential for their efficacy have not been fully characterized. In this paper, I review the studies that attempted to identify the key mediators of MSCs that are involved in their effects on disease using in vivo models. More specifically, studies are discussed in which reductions in the efficacy of MSCs in animal models of disease were induced by the absence of key mediators. The target diseases were lung, joint, cerebral nerve, or cardiac diseases and graft-versus-host disease (GVHD). The following molecules were identified and are discussed herein: TSG-6, VEGF, KGF, HGF, claudin-4, ANXA1, MANF, PYCR1, integrin β1, PDGFRβ, type-II collagen, CD151, TIMP3, TGF-β1, BDNF, COX-2, Botch, IL-1β, CTRP3, CXCR4, miR-34c, FSTL1, IDO, iNOS, IFNγR1, PGES, Chi3l1, and IL-6. These are key mediators of the efficacy of MSCs in vivo.
Insights
Mesenchymal stem cells (MSCs) show therapeutic promise, but their mechanisms remain unclear. This review identifies key molecules mediating MSC efficacy in various diseases, crucial for future treatments.
Area of Science:
- Regenerative Medicine
- Cell Therapy
- Immunology
Background:
- Mesenchymal stem cells (MSCs) are investigated for treating diverse diseases.
- Understanding MSC mechanisms of action is critical for clinical translation.
- Key molecules mediating MSC efficacy are not fully characterized.
Purpose of the Study:
- To review studies identifying key mediators of MSC efficacy in vivo.
- To highlight molecules essential for MSC therapeutic effects in disease models.
Main Methods:
- Literature review of studies using in vivo models.
- Analysis of studies where MSC efficacy was reduced by the absence of specific mediators.
- Focus on lung, joint, cerebral nerve, cardiac diseases, and graft-versus-host disease (GVHD).
Main Results:
- Identified numerous key mediators of MSC efficacy, including TSG-6, VEGF, HGF, ANXA1, TGF-β1, BDNF, IL-6, and IDO.
- These molecules were characterized through their absence-induced reduction in MSC therapeutic effects in animal models.
- The review covers a broad spectrum of MSC-related therapeutic targets.
Conclusions:
- Elucidating these key mediators is vital for advancing MSC-based therapies.
- Characterization of these molecules will facilitate the development of more effective MSC treatments.
- Further research into these mediators will accelerate MSC clinical approval and application.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...